News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
887,111 Results
Type
Article (89048)
Company Profile (555)
Press Release (797490)
Multimedia
Podcasts (252)
Webinars (38)
Section
Business (267134)
Career Advice (4168)
Deals (40047)
Drug Delivery (182)
Drug Development (91830)
Employer Resources (208)
FDA (18627)
Job Trends (17507)
News (399010)
Policy (40028)
Tag
2027 BioCapital Elite (1)
2027 BioCapital Standard (1)
2027 BioMidwest Elite (2)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (2)
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (3)
2027 Biotech Beach Elite (2)
2027 Biotech Beach Standard (2)
2027 Genetown Elite (4)
2027 Genetown Standard (7)
2027 Pharm Country Elite (2)
2027 Pharm Country Premier (1)
2027 Pharm Country Standard (7)
Academia (3072)
Academic (2)
Accelerated approval (60)
ADA (50)
Adcomms (43)
Allergies (213)
Alliances (56991)
ALS (247)
Alzheimer's disease (2059)
Antibody-drug conjugate (ADC) (614)
Approvals (19044)
Artificial intelligence (951)
ASCO (345)
Autoimmune disease (399)
Automation (71)
Bankruptcy (409)
Best Places to Work (12635)
BIO (80)
BIOSECURE Act (23)
Biosimilars (266)
BioSpace Insights (235)
Biotechnology (336)
Bladder cancer (223)
Brain cancer (87)
Breast cancer (878)
Cancer (6956)
Cardiovascular disease (588)
Career advice (3607)
Career pathing (56)
CAR-T (407)
CDC (77)
Celiac Disease (3)
Cell therapy (1130)
Cervical cancer (60)
Clinical research (79601)
Collaboration (2536)
Commercialization (6)
Company closure (8)
Compensation (1628)
Complete response letters (119)
COVID-19 (3051)
CRISPR (131)
C-suite (1419)
Cystic fibrosis (170)
Data (9208)
Decentralized trials (3)
Denatured (97)
Depression (209)
Dermatology (115)
Diabetes (741)
Diagnostics (7709)
Digital health (76)
Diversity (14)
Diversity, equity & inclusion (49)
Drug discovery (485)
Drug pricing (248)
Drug shortages (39)
Duchenne muscular dystrophy (345)
Earnings (102885)
Editorial (81)
Employer branding (25)
Employer resources (178)
Events (139231)
Executive appointments (1260)
FDA (23020)
Fibrodysplasia Ossificans Progressiva (10)
Friedreich's ataxia (24)
Frontotemporal dementia (37)
Funding (2068)
Gene editing (287)
Generative AI (97)
Gene therapy (885)
GLP-1 (1310)
Government (5577)
Grass and pollen (8)
Guidances (433)
Healthcare (21286)
Hematology (198)
HIV (110)
Huntington's disease (73)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (123)
Immunology and inflammation (377)
Immuno-oncology (125)
Indications (235)
Infectious disease (3467)
Inflammatory bowel disease (248)
Inflation Reduction Act (17)
Influenza (156)
Intellectual property (345)
Interviews (824)
IPO (18025)
IRA (61)
Job creations (5209)
Job search strategy (2873)
JPM (73)
Kidney cancer (27)
Labor market (130)
Layoffs (700)
Leadership (57)
Legal (10173)
Licensing (3)
Liver cancer (112)
Longevity (38)
Lung cancer (924)
Lymphoma (502)
Machine learning (70)
Management (69)
Manufacturing (1341)
Marketing (12)
MASH (233)
Medical affairs (1)
Medical device (15348)
Medtech (15570)
Mergers & acquisitions (23418)
Metabolic disorders (1909)
mRNA (283)
Multiple sclerosis (217)
NASH (24)
Neurodegenerative disease (555)
Neuropsychiatric disorders (134)
Neuroscience (3925)
Neurotech (2)
NextGen: Class of 2026 (7717)
Non-profit (5151)
Now hiring (87)
Obesity (903)
Opinion (385)
Ovarian cancer (258)
Pain (301)
Pancreatic cancer (380)
Parkinson's disease (436)
Partnered (43)
Patents (713)
Patient recruitment (872)
Peanut (72)
People (68336)
Pharmaceutical (81)
Pharmacy benefit managers (38)
Phase 1 (24589)
Phase 2 (34571)
Phase 3 (26002)
Pipeline (10859)
Policy (411)
Postmarket research (3561)
Preclinical (11020)
Press Release (72)
Prostate cancer (367)
Psychedelics (82)
Radiopharmaceuticals (390)
Rare diseases (1378)
Real estate (7467)
Recruiting (83)
Regulatory (30884)
Reports (79)
Research institute (2784)
Resumes & cover letters (655)
Rett syndrome (47)
RNA editing (31)
RSV (100)
Schizophrenia (203)
Series A (354)
Series B (258)
Service/supplier (15)
Sickle cell disease (136)
Special edition (33)
Spinal muscular atrophy (193)
Sponsored (55)
Startups (4379)
State (2)
Stomach cancer (21)
Supply chain (155)
Tariffs (105)
The Weekly (152)
Vaccines (1346)
Venture capital (145)
Weight loss (614)
Women's health (151)
Worklife (25)
Date
Today (155)
Last 7 days (605)
Last 30 days (2231)
Last 365 days (33460)
2026 (19738)
2025 (33213)
2024 (37864)
2023 (42564)
2022 (53928)
2021 (58720)
2020 (57663)
2019 (51334)
2018 (39119)
2017 (37188)
2016 (38329)
2015 (44432)
2014 (39672)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1299)
Alabama (107)
Alaska (7)
Arizona (422)
Arkansas (16)
Asia (52552)
Australia (9238)
California (15002)
Canada (4198)
China (1708)
Colorado (645)
Connecticut (666)
Delaware (465)
Europe (121195)
Florida (2272)
Georgia (489)
Hawaii (5)
Idaho (70)
Illinois (1315)
India (116)
Indiana (691)
Iowa (25)
Japan (647)
Kansas (149)
Kentucky (59)
Louisiana (65)
Maine (92)
Maryland (1798)
Massachusetts (10962)
Michigan (431)
Minnesota (840)
Mississippi (7)
Missouri (172)
Montana (37)
Nebraska (31)
Nevada (160)
New Hampshire (92)
New Jersey (3977)
New Mexico (36)
New York (3961)
North Carolina (1987)
North Dakota (11)
Northern California (7519)
Ohio (472)
Oklahoma (29)
Oregon (47)
Pennsylvania (2930)
Puerto Rico (33)
Rhode Island (54)
South America (1671)
South Carolina (92)
South Dakota (2)
Southern California (5924)
Tennessee (245)
Texas (2444)
United States (53591)
Utah (453)
Vermont (2)
Virginia (376)
Washington D.C. (88)
Washington State (1219)
West Virginia (4)
Wisconsin (168)
Wyoming (2)
There are 887,111 results that match your search.
Filters
Sort By
Relevance
Relevance
Newest
Oldest
FDA
Replimune overcomes ‘messy data’ to secure positive adcomm vote for melanoma therapy
The FDA’s Cellular, Tissue and Gene Therapies advisory committee voted 10 to 3 in favor of Replimune’s immunotherapy for advanced melanoma in combination with Bristol Myers Squibb’s Opdivo, but trial design was a major sticking point as the panel deliberated.
July 30, 2026
·
5 min read
·
Michael Gibney
Press Releases
Medexus Schedules First Fiscal Quarter 2027 Conference Call
July 30, 2026
·
3 min read
Press Releases
Noveris Health Sciences Joins BioAlberta
July 30, 2026
·
4 min read
Press Releases
Therma Bright Inc. Completes Debt Settlements
July 30, 2026
·
3 min read
Press Releases
TempraMed Uplists to OTCQB Venture Market and Achieves DTC Eligibility, Expanding Access to U.S. Investors
July 30, 2026
·
5 min read
Press Releases
Bachem Confirms Growth and Expects a Strong Second Half 2026
July 30, 2026
·
5 min read
Press Releases
Sino Biological Launches SuperNuclease® Pro with Free Trial Program
July 30, 2026
·
4 min read
Earnings
BMS’ ‘big beat’ clouded by Cobenfy, heart disease data delays
Strong quarterly results are prompting Bristol Myers Squibb to lift its 2026 outlook, though the company is facing another delay for key Cobenfy Alzheimer’s data and a pushed-back readout for milvexian.
July 30, 2026
·
4 min read
·
Gabrielle Masson
Earnings
Regeneron’s ‘aversion’ to M&A questioned as bumper Q2 builds war chest
Calls for Regeneron to step up dealmaking have intensified as the company has established an $18 billion cash pile and suffered clinical trial setbacks.
July 30, 2026
·
2 min read
·
Nick Paul Taylor
Press Releases
Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041
July 30, 2026
·
5 min read
1 of 88,712
Next